Alzheimer's disease therapies
Sep 02, 2025
FDA Approves Eisai & Biogen’s LEQEMBI IQLIK for Maintenance Treatment of Early Alzheimer’s; Travere Therapeutics Gains FDA Nod for FILSPARI REMS Update in IgA Nephropathy; Vanda Pharmaceuticals’ VGT-1849B Granted FDA Orphan Drug Status for Polycythemia Vera; Teva Launches First FDA-Approved Generic SAXENDA for Weight Loss; Sanofi’s WAYRILZ Gets FDA Approval as First BTK Inhibitor for Immune Thrombocytopenia
FDA Approves Eisai & Biogen’s LEQEMBI IQLIK for Maintenance Treatment of Early Alzheimer’s Eisai Co., Ltd. and Biogen Inc. announced that the FDA has approved the Biologics License Application (BLA) for LEQEMBI IQLIK (lecanemab-irmb), a once-weekly 360 mg subcutaneous autoinjector designed for maintenance do...
Read More...
Jul 01, 2025
Sobi’s GAMIFANT Approved by FDA as First Treatment for Macrophage Activation Syndrome in Still’s Disease; GSK Cuts RTS,S Malaria Vaccine Price for Children in Endemic Regions to Under $5; Schrödinger’s SGR-1505 Receives FDA Fast Track Designation for Relapsed/Refractory Waldenström Macroglobulinemia; Ultragenyx’s GTX-102 Granted FDA Breakthrough Therapy Designation for Angelman Syndrome; Eli Lilly’s AMYVID Label Updated by FDA to Support Alzheimer’s Disease Diagnosis
FDA Approves Sobi’s GAMIFANT as the First Treatment for Macrophage Activation Syndrome in Still’s Disease In a major advancement for rare inflammatory conditions, the FDA has approved GAMIFANT (emapalumab-lzsg) for the treatment of hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MA...
Read More...
Apr 18, 2025
Groundbreaking Alzheimer’s Therapies: From Pipeline to Patient Care
The Alzheimer's and Parkinson's Diseases (AD/PD) 2025 International Conference, conducted in April in Vienna, Austria, and online, stands as a pivotal event in neurodegenerative disease research. This hybrid gathering brings together global experts to delve into the latest advancements in Alzheimer’s and Parkinson’...
Read More...
Feb 25, 2025
Alzheimer’s Disease: Navigating the Rising Incidence, Evolving Treatments, and Market Dynamics
Alzheimer’s disease is more than just memory loss—it’s a progressive neurodegenerative disorder that slowly erodes cognition, behavior, and independence. What may begin as occasional forgetfulness or difficulty recalling names can soon escalate into disorientation, personality changes, and an inability to carry out...
Read More...
Feb 12, 2025
Exploring the Current Alzheimer’s Disease Drug Development Pipeline
Alzheimer's disease continues to pose a significant challenge to global healthcare systems, with the 7MM reporting approximately 16 million diagnosed prevalent cases in 2023. This rising AD prevalence highlights an urgent need for innovative treatments to mitigate the growing disease burden on both patients and car...
Read More...
Jul 08, 2024
A New Dawn in Alzheimer’s Disease Treatment: Eli Lilly’s Donanemab Wins FDA Approval
The world of Alzheimer’s disease treatment witnessed a groundbreaking moment recently as the FDA approved Eli Lilly’s donanemab, marketed as KISUNLA. This new drug brings hope to millions of patients and their families struggling with this debilitating disease. Let us delve into the fascinating journey of donanemab...
Read More...
Oct 23, 2019
Biogen seeks the FDA approval to revive its Alzheimer’s drug Aducanumab
Not a long time ago this year, Biogen announced the halting of Phase III clinical trials, EMERGE and ENAGE, of its most looked upon drug aducanumab under simulations for the treatment of Alzheimer's disease called futility analysis. The drug was designed to help patients struggling with mild cognitive impairmen...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
